AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

Can we change the disease biology of multiple myeloma?

(2012) Ivan Borrello   LEUKEMIA RESEARCH

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

Systematic evaluation of medium-throughput mRNA abundance platforms

(2012) S. D. Prokopec et al.   RNA

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

(2011) Aisha Masood et al.   BRITISH JOURNAL OF HAEMATOLOGY

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

(2011) Asher A. Chanan-Khan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia

(2011) Pooja P Advani et al.   Expert Opinion on Drug Metabolism & Toxicology

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

(2011) Sikander Ailawadhi et al.   LEUKEMIA & LYMPHOMA

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Expression of Bcl11b Leads to Chemoresistance Accompanied by G1 Accumulation

(2010) Piotr Grabarczyk et al.   PLoS One

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

(2010) W J Placzek et al.   Cell Death & Disease

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

(2009) Asher A. Chanan-Khan et al.   LEUKEMIA & LYMPHOMA

Bcl-2-family proteins and hematologic malignancies: history and future prospects

(2008) J. C. Reed   BLOOD

R-(-)−gossypol (AT-101) activates programmed cell death in multiple myeloma cells

(2008) Michael P. Kline et al.   EXPERIMENTAL HEMATOLOGY

Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents

(2008) Benjamin D. Zeitlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct multiplexed measurement of gene expression with color-coded probe pairs

(2008) Gary K Geiss et al.   NATURE BIOTECHNOLOGY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY